Skystar Bio-Pharmaceutical, a leading bio-pharmaceutical company in China, announced that it has entered into an agreement with TNI-Penta for research and development of new veterinary pharmaceutical products. The new products are to be based on the efficacy of Methionine Enkephalin (MEK) for use in veterinary medicine.

Skystar had previously announced entering into a Letter of Intent for this joint venture with TNI-Penta. TNI-Penta's executive team, lead by Dr. Nicholas Plotnikoff, met with Skystar's executive management and top research team in Xi'an, China in early January and signed a three-year agreement whereby TNI-Penta will provide MEK Active Pharmaceutical Ingredients (API), requisite technology, intellectual property rights, and technical and consulting services to Skystar to help in performing tests in a controlled environment to evaluate the safety, duration of immunity, minimum effective dosage and protective efficacy of the newly developed drugs containing MEK API.

Once the products have successfully passed all testing stages, Skystar will file for government approval for mass production and sale throughout China. TNI-Penta will receive an average of 9% of the gross revenues realized from sale of any new product developed through this joint venture.

Source:未知